Triptorelin Acetate
GnRH agonist
Decapeptide GnRH agonist with D-tryptophan at position 6, studied for pituitary receptor desensitisation and lowered LH, FSH and sex steroids.
Evidence level. Published human clinical data exists, from trials or approved use. About the badges
- Class
- GnRH agonist
- Category
- Reproductive & Endocrine
- Type
- Single compound
- Development and regulatory status
- Approved prescription drug (GnRH agonist; prostate cancer, precocious puberty)
What researchers study
Synthetic decapeptide GnRH agonist with a D-tryptophan substitution at position 6. After an initial stimulation it desensitises pituitary GnRH receptors, lowering LH, FSH and sex-steroid levels.
Research areas
- Pituitary desensitisation and hormone-suppression models
- Pubertal suppression in rodent models
- Central precocious puberty outcome studies
- Stimulation-test comparisons with gonadorelin
Reported findings
Summaries of published results. Each one is tagged with the type of study behind it. They describe research outcomes and are not claims about any product. Why study type matters.
- rodent
In Wistar rats, depot triptorelin at pubertal onset suppressed pubertal maturation, downregulated pituitary Gnrhr and Lhb, and produced sex-dependent metabolic changes
- review
A systematic review examined final height and long-term health effects of GnRH agonist therapy in boys with central precocious puberty
- review
Excessive GnRH agonist or antagonist exposure in women was reported to give undetectable serum LH
Studied alongside
Compounds that appear together in research because their mechanisms complement each other, or as comparators. The reasons given are research reasoning, not recommendations for use.
- Gonadorelinnative GnRH used in stimulation-test comparisons with triptorelin
- Alarelinrelated GnRH agonist
- HMGgonadotropin stimulation commonly follows GnRH-agonist pituitary suppression in IVF studies
- HCGLH-like trigger studied after GnRH-agonist suppression
